Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02309723 · ClinicalTrials.gov registry record · NA
Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.
A NA study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 315
- Enrollment target
NCT02309723: Completed NA study, sponsored by Tufts Medical Center.
NCT02309723 is a NA study that has completed, run by Tufts Medical Center. The registered enrollment target is 315 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02309723, a NA study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 315 participants
- Enrollment target
Study Summary
When older patients develop cognitive problems - like memory loss - there may be any of several underlying causes, sometimes occurring in combination. Clinicians have a better chance of providing appropriate treatment if they understand what the cause of the problem is. A diagnostic tool can help the patient by helping the clinician to make a more accurate diagnosis. This study investigates whether a new diagnostic tool - beta amyloid imaging - may potentially improve medical practice. The tool can potentially improve practice only if it can influence clinical judgment. This study investigates whether the provision of beta amyloid imaging information influences clinical judgment. The investigators will conduct a survey that presents clinicians with descriptions of hypothetical older patients with cognitive complaints. Some of the respondents also receive beta amyloid imaging information. The investigators will test the investigators hypothesis that the information will affect diagnostic judgment and management recommendations by comparing the responses of clinicians who receive the beta amyloid information to the responses of clinicians who do not.
Primary Outcome
Proportion of respondents who identify Alzheimer's Disease as the sole or a contributing factor that is responsible for the patient's cognitive complaint.
Interventions
- DEVICE Beta amyloid imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2013-09 |
| Est. Completion | 2013-11 |
| Phase | NA |
What the finished NCT02309723 record still lists
NCT02309723 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 1 intervention - of which Beta amyloid imaging is the first listed.
NCT02309723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02309723 about?
NCT02309723 is a clinical study titled "Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.". When older patients develop cognitive problems - like memory loss - there may be any of several underlying causes, sometimes occurring in combination. Clinicians have a better chance of providing appropriate treatment if they understand what the cause of the problem is. A diagnostic tool can help th...
What is the current status of trial NCT02309723?
This trial is currently completed. It is a NA study. The enrollment target is 315 participants. The study started on 2013-09. Estimated completion is 2013-11.
What interventions are being tested in trial NCT02309723?
The interventions under investigation include: Beta amyloid imaging (DEVICE).
Who is sponsoring clinical trial NCT02309723?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02309723's enrollment target sits among peer trials
315 323rd of 2000 higher than 1,678 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia